Suppr超能文献

钠-葡萄糖协同转运蛋白 2 抑制剂卡格列净通过抑制核苷酸结合域、富含亮氨酸重复家族、吡咯烷酮域-3 炎性小体缓解血管钙化。

Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome.

机构信息

Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510280, China.

Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, 253 Industrial Avenue, Guangzhou, 510280, China.

出版信息

Cardiovasc Res. 2023 Oct 24;119(13):2368-2381. doi: 10.1093/cvr/cvad119.

Abstract

AIMS

Vascular calcification (VC) is prevalent in pathological processes such as diabetes, chronic kidney disease (CKD), and atherosclerosis, but effective therapies are still lacking by far. Canagliflozin (CANA), a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes mellitus and exhibits beneficial effects against cardiovascular disease. However, the effect of CANA on VC remains unknown. In this study, we hypothesize that CANA protects against VC.

METHODS AND RESULTS

Micro-computed tomography analysis and alizarin red staining revealed that CANA treatment prevented aortic calcification in CKD rats and in VitD3-overloaded mice. Moreover, CANA alleviated the calcification of rat and human arterial rings. Alizarin red staining revealed that calcification of rat and human vascular smooth muscle cells (VSMCs) was attenuated by CANA treatment and this phenomenon was confirmed by calcium content assay. In addition, CANA downregulated the expression of osteogenic differentiation markers Runx2 and BMP2. Of interest, qPCR and western blot analysis revealed that CANA downregulated the expression of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and the downstream signalling molecules Caspase-1 and IL-1β in VSMCs as well. Both NLRP3 inhibitor MCC950 and knockdown of NLRP3 by siRNA independently resulted in decreased calcification of VSMCs. By contrast, activation of NLRP3 exacerbated VSMC calcification, and this effect was prevented by the addition of CANA.

CONCLUSIONS

Our study for the first time demonstrates that CANA exerts a protective effect on VC at least partially via suppressing the NLRP3 signalling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for VC.

摘要

目的

血管钙化(VC)在糖尿病、慢性肾脏病(CKD)和动脉粥样硬化等病理过程中较为常见,但迄今为止,仍缺乏有效的治疗方法。钠-葡萄糖共转运蛋白 2 抑制剂卡格列净(CANA)已被批准用于治疗 2 型糖尿病,并显示出对心血管疾病有益的作用。然而,CANA 对 VC 的影响尚不清楚。在本研究中,我们假设 CANA 可预防 VC。

方法和结果

使用微计算机断层扫描分析和茜素红染色发现,CANA 治疗可预防 CKD 大鼠和 VitD3 超负荷小鼠的主动脉钙化。此外,CANA 可减轻大鼠和人动脉环的钙化。茜素红染色显示,CANA 处理可减轻大鼠和人血管平滑肌细胞(VSMCs)的钙化,钙含量测定也证实了这一现象。此外,CANA 下调了成骨分化标志物 Runx2 和 BMP2 的表达。有趣的是,qPCR 和 Western blot 分析显示,CANA 下调了 VSMCs 中核苷酸结合域、富含亮氨酸重复序列、吡喃结构域蛋白 3(NLRP3)及其下游信号分子 Caspase-1 和 IL-1β的表达。NLRP3 抑制剂 MCC950 和 siRNA 敲低 NLRP3 均可独立减少 VSMCs 的钙化。相反,NLRP3 的激活加剧了 VSMC 的钙化,而 CANA 的加入则阻止了这一作用。

结论

我们的研究首次表明,CANA 至少部分通过抑制 NLRP3 信号通路对 VC 发挥保护作用。因此,CANA 的补充以及 NLRP3 炎性小体的抑制为 VC 提供了一种潜在的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验